adaptive(US) | $7,000,000 | (Apr 23, 2025)
Tally(US) | $8,000,000 | (Apr 23, 2025)
Recce | $4,000,000 | (Apr 23, 2025) Certified by Founder
Lodge
HI-Bio
start up
United States
- South San Francisco, California
- 05/01/2024
- Series B
- $95,000,000
Human Immunology Biosciences (HI-Bio) is leading clinical immunology into its next chapter with therapies that target cellular drivers of disease. HI-Bio uses a precision medicine approach to deliver therapies for patients with the auto-immune, allergic and inflammatory diseases that can together be referred to as immune-mediated diseases (IMDs).
- Industry Biotechnology Research
- Website https://hibio.com/
- LinkedIn https://www.linkedin.com/company/hibio/about/
GreenFi | $17,000,000 | (Apr 23, 2025)
UbiQD, Inc. | $20,000,000 | (Apr 23, 2025)
Arch Network | $13,000,000 | (Apr 23, 2025)
Spur | $4,500,000 | (Apr 22, 2025)
Capsule | $12,000,000 | (Apr 22, 2025)
CSignum | $8,021,670 | (Apr 22, 2025)